

Dr Peter Muller
Maternal-Fetal Medicine
Women's and Children's Hospital




Avoid the Quick Sand – Aneuploidy Screening Common Questions


Never know what you are going to find!



History




% of confinements undergoing invasive prenatal tests (Δ)



Muller et al, AJOG, April 2007

AMA

undergoing invasive prenatal tests (◇)



Muller et al, AJOG, April 2007


Number of invasive prenatal tests to diagnose one aneuploid fetus

| Year | # * |
|------|-----|
| 1996 | 47 |
| ↓ | ↓ |
| 2005 | 15 |


* $p < 0.001$

Muller et al, AJOG, April 2007


What is Cell-Free DNA?




History - cfDNA



% of births with diagnostic testing Victoria



Indication for prenatal test Victoria



Victorian Population

- Proportion of births have invasive testing
 - 2.7%
- Yield of invasive tests
 - 20%
 - 1/5 positive invasive test

Question 1

- Time to offer NIPT to all women, low or high risk?

The NEW ENGLAND
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812


APRIL 23, 2015

VOL. 372 NO. 17

Cell-free DNA Analysis for Noninvasive Examination of Trisomy

Mary E. Norton, M.D., Bo Jacobsson, M.D., Ph.D., Geeta K. Swamy, M.D., Louise C. Laurent, M.D., Ph.D.,
Angela C. Ranzini, M.D., Herb Brar, M.D., Mark W. Tomlinson, M.D., Leonardo Pereira, M.D., M.C.R.,
Jean L. Spitz, M.P.H., Desiree Hollemon, M.S.N., M.P.H., Howard Cuckle, D.Phil., M.B.A.,
Thomas J. Musci, M.D., and Ronald J. Wapner, M.D.

cfDNA vs cFTS



Norton M et al, NEJM;2015


cfDNA vs cFTS

- NIPT false positive $1/10^{\text{th}}$ of multiple marker screening
- PPV with NIPT higher than PPV of FTCS among high risk women

Question 2

- Should both FTCS and NIPT be offered?
- Or Just one?

cfDNA vs cFTS



Norton M et al, NEJM;2015

Both!!

**So I will not miss an atypical
chromosomal abnormality.**

What happens in the “Real world” Victoria

1. Performance of different prenatal screening strategies
2. Residual risk of major chromosomal abnormality following low risk result.

1. In other words, what is missed?

Lindquist A et al UOG. 2020;56:215.

Victoria 2015

| Screening pathway | Sens T21 | Sens T21,T13,T18 | Spec T21, T13, T18 | Screen Positive |
|-------------------|----------|------------------|--------------------|-----------------|
| cFTS alone | 87.95% | 89.57% | 97.25 | 2.94 |
| cfDNA alone | 100% | 100% | 99.93 | 1.21% 2.42% |
| STSS | 50% | 60% | 93.17 | 6.92% |

Lindquist A et al UOG. 2020;56:215.

Residual Risk major chromosomal abnormality – low risk screening

| Prenatal Screening Pathway | % Risk |
|----------------------------|----------------------|
| Low risk cFTS | 0.084% (1:1188) * |
| Low risk cfDNA | 0.13% (1:762) * |

* = NS

Lindquist A et al UOG. 2020;56:215.

Conclusion

- Although non-significant difference in residual risk of any major abnormality between cFTS (1:1188) and cfDNA (1:762)
- cfDNA with fewer live born infants with major chromosomal abnormality
- Conclusion:
 - Do not do both as a type of screening.

But we need the PAPP-A?????

| PAPP-A Level | FGR (BW < 10 th %) | PTB < 34 weeks |
|-------------------------------|-------------------------------|--------------------|
| <5 th % (0.4 MoM) | 14 ⁰ % | 2.3 ⁰ % |
| < 1 st % (0.2 MoM) | 24 ⁰ % | 2.5 ⁰ % |

PAPP-A

| Biochemistry | Risk of microarray abnormality not detected by NIPT |
|---------------------------------------|-----------------------------------------------------|
| PAPP-A < 0.2 MoM (<1 st %) | 4% |
| BHCG < 0.2 MoM (<1 st %) | 7% |
| BHCG > 5.0 MoM (>99 th %) | 0.5% |

Why would you? PAPP-A

- cFTS call back rate
 - 5% overall
 - Close to 20% over 35
 - Close to 25% ≥ 40
- PAPP-A $< 1^{\text{st}}\%$ is all we care about
 - 5% call back rate for high Trisomy 21
 - to get a 1% modest risk of SGA $< 10^{\text{th}}\%$

College and Society Statements

- RANZCOG – July 2018 - Acceptable first-line screening tests:
- First Trimester Combined Screening
- OR
- cell-free DNA (cfDNA)-based screening.
patient demographics, and individual patient characteristics.

Question 2?

Both as first line?

NO!

Lets Stop it!!

Question 3

- After NIPT, is there still need for First Trimester anatomy ultrasound?



First Trimester Ultrasound Benefits

- Early detection of multiple pregnancy
 - (and probably chorionicity)
- Improved gestational dating
 - Fewer inductions for post dates.

Whitworth M et al, Cochrane Database 2015

- Major fetal abnormalities
 - Early genetic termination of pregnancy

First Trimester Ultrasound Benefits

- Systematic review
 - 51% detection

Rossi AC et al O&G Vol 122, No. 6, Dec 2013

Low risk vs high risk

- Systematic review
- 32% detection in low risk
- 60% detection in high risk

Role of 11-14 week scan with negative cfDNA

- Negative cfDNA
 - 3.5% had unexpected finding
 - 2.1 with fetal abnormality


If perform cfDNA, when should we do the ultrasound.

“Best Bang for your buck”


11 + 6 weeks




13 + 2 weeks




11 + 6 weeks





13 + 2 weeks



11 + 6 weeks





13 + 0 weeks




13 + 0 weeks



13 + 2 weeks



13 + 2 weeks




TV scanning



B68°/V75°
70 Hz
Surface
Qual mid2
Mix0/100
CRI 3/VSRI 3
3D Static



3D



B68°/V75°
70 Hz
Surface
Qual mid2
Mix0/100
CRI 3/VSRI 3
3D Static



3D

11-13 weeks anomaly detection

Syngelaki A et al, UOG, 2019;54:468

| Detection % | Abnormality |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 100% | Gastroschisis, omphalocele, acrania, Body stalk anomaly, Alobar holoprosencephaly, encephalocele, |
| >50% | Open NTD (59%), HLHS (92%), AVSD (91%), complex heart defect (60%), Absent extremities (75%), fetal akinesia (73%), lethal skeletal dysplasia (71%), Lower UT obstruction (71%) |
| <10% | Agensis Corpus callosum, isolated cleft lip, CPAM, VSD, unilateral renal agenesis, abdominal cysts, |


First Trimester Ultrasound

- **RANZCOG College Statement (2018):**
 - *"Women who choose to have cfDNA as a primary screening test should still be offered the opportunity to have an 11-13 week ultrasound for an early structural assessment, as 50% of major abnormalities can now be detected at this gestation".*

Question 4

- How should a “positive” NIPT be interpreted?


PPV: cFTS vs NIPT vs low risk NIPT



Norton ME et al NEJM, 2015

Question 5

- NIPT in sex chromosomal abnormalities (SCA)?
- To do or not to do?



Importance in screening!

- Clinically significant abnormality that has significant impact on development !

Sex Chromosome Abn (SCA) Counselling


- High prevalence
 - Potential High frequency of Positive NIPT
 - 1%
- Phenotypic features
 - Highly variable
- Relatively few serious physical abnormalities

Sex Chromosome Abn (SCA) Counselling

- Phenotypic ascertainment bias
 - Postnatal/adult –
 - over-representation of severe clinical outcome
 - Prenatal detection
 - Better outcomes seen
- Benefit from early screening and medical intervention

PPV: SCA

PPV



Norton M et al NEJM 2015 and Bianchi DW, O&G, Vol 125, Feb. 2015

13,000 Aussie males don't know they have Klinefelter's Syndrome and remain untreated

Are you one of them?



Normal
Adult

Abnormal
Adult




Self examination
is the first step to
your wellbeing.

The physical signs of Klinefelter's Syndrome are:

- Under-functioning testicles that are hard and abnormally small – peanut size.
- infertility (recent technological advances can assist KS males to father a biological child)
- reduced life-span if untreated.
- Increased risk of both diabetes and heart disease.
- Rudimentary breast development, fatty hips and thighs, poor muscle strength and mass.
- Psychological issues including depression.
- KS boys often have learning, speech, physical and attitude problems.

• When diagnosed, treatment provides KS males with vastly improved mental and physical health and lifestyle opportunities.

Please consult your doctor.



LAWLEY

www.lawleypharm.com.au

A Lawley men's health initiative.

However

- RCT 47XXy - Treating with low testosterone age 4-12
- Positive effects on visual-motor integration and psychosocial function, without affecting most other motor or cognitive outcomes
- Positive effects on several aspects of anxiety/depression and social functioning, without adverse effects on behavior.

Sex Chromosome Abn (SCA) Counselling

- Parental decision making
 - Significant decrease in proceeding GTOP with multidisciplinary counselling
 - Need to provide accurate, unbiased and updated information

ISPD 2015


- *"Women should have the option to separately accept or reject the sex chromosome analysis"*

Question 7

- What is the chance of atypical aneuploidy occurring in high risk FTCS and “low risk” NIPT?
- How does ultrasound help?

Western Australia

2007-2009





Western Australia- 2007-2009

53,000 women screened

- *“Fetal Sonographic appearance was likely to have led to recommendation for invasive test”*
- *FTS risk <1:50 + Low risk NIPT + no ultrasound findings*
- *Residual risk of 0.33%*

Question 9

- What really is the risk of miscarriage from invasive testing?



Procedure related loss meta-analysis

- Amniocentesis
 - $\ll 1:300.$?1:909
- CVS
 - $\ll 1:300$?1:454

Counseling

- “Best case scenario”
 - *Rieder W et al ANZJOG. 2018. 58:397-403*
- Medical legal risk to over estimate risk and miss atypical chromosomal abnormalities
- Optimal choice based on experienced operator
 - ISPD Newsletter Vol 1, Number 1, December 2012

Question 11

What is considered an elevated NT?

Specialized morphology?

Risk of selected structural abnormalities in infants after increased nuchal translucency measurement

Rebecca J. Baer, MPH; Mary E. Norton, MD; Gary M. Shaw, DrPH; Monica C. Flessel, PhD; Sara Goldman, MPH; Robert J. Currier, PhD; Laura L. Jelliffe-Pawłowski, PhD

Background risk of major birth defects = 2%

| NT | <90 th % | 90-94 th % | 95 th -99 th % 2.7-3.4 | 99 th % ≥ 3.5mm |
|-----------------|---------------------|-----------------------|-------------------------------------------------|-------------------------------|
| Structural Abnl | 1.7% | 2.1% | 2.7% | 5.2% |

NIPT or Invasive testing for all > 3.5 mm?

- Isolated NT ≥ 3.5 mm
Incremental yield of 4.0% to standard karyotype
- Significant limitations for NIPT
- We would offer invasive diagnostic testing.

NT 3.0 to 3.4

| NT | Microarray Abnomrlity | Standard NIPT LR | Genome Wide NIPT |
|------------------|-----------------------|------------------|------------------|
| Background | 1% | | |
| NT < 3.0 mm | 0.8% | | |
| NT 3.0-3.4 mm | 4.7% | 1.9% | 1.5% |

Increased NT > 1.9 MoM





FIGURE 2 Distribution of nuchal translucency measurements among 81,244 singleton pregnancies in Victoria, 2015–2016. CRL, crown rump length; NT, nuchal translucency, MoM, multiples of the median. *Source:* Data courtesy of Leonard Bonacquisti, Victorian Clinical Genetics Services. Software: Alpha Version 8.0.16281.67, Logical Medical Systems Ltd, London, United Kingdom [Colour figure can be viewed at wileyonlinelibrary.com]


Question Genome Wide NIPT

Should we tick the box?



Where does cfDNA come from?


What is Cell-Free DNA?



PRENATAL DIAGNOSIS


6

Transabdominal Chorionic Villus Sampling (CVS)



Question Genome Wide NIPT


Should we tick the box?



- Common (T21, T18, T13) which account for over 70% of chromosomal abnormalities seen standard karyotype
- There is high level evidence for its use.
- Genome Wide NIPT
 - Clinpath
 - Repromed

Question Genome Wide NIPT

Should we tick the box?



- Rare Autosomal Trisomies (RATs) or large segmental chromosomal abnormalities
 - 1:250 to 1:300
 - So common
- 7.5 Mb size
- Double your high risk NIPT result


Genome Wide NIPT

- True complete fetal trisomies (other than T21, T18 or T13) are likely incompatible with normal pregnancy progression.
- A NIPT screen positive for RAT's, a normal ultrasound will indicate confined placental mosaicism (CPM) in 97% of the time.
- Fetal Mosaicism is rare 1.5% and ultrasound may be normal in 29% of cases
- CPM is a risk factor for fetal growth restriction, particular CPM of Trisomy 16.
- Approximately one in three NIPT high risk RAT will develop fetal growth restriction.


Genome Wide NIPT

- Suggest
 - Pretest counselling
 - For positive NIPT for RATs, the current recommendation is to first perform high level 12-13 week ultrasound
 - If the ultrasound is normal, since CPM will be the most common reason for the NIPT result, we recommend amniocentesis at 15 + weeks.
 - This is because NIPT is testing the same area that tested with CVS, placental DNA.


Recommendations




Recommendations



Recommendations




Recommendations



Preeclampsia Screening

Another talk



Thank You

